NCT05590221 2024-01-08
Relmacabtagene Autoleucel as First-Line Therapy for High-Risk Large B-Cell Lymphoma
Peking University Cancer Hospital & Institute
Phase 2 Unknown
Clinical Trials
76 trialsNCT04715217 2023-12-29
Targeting CD19 and CD22 CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory B Cell Lymphoma
Shanxi Province Cancer Hospital
Phase 1/2 Unknown
NCT05927558 2023-12-29
Salvage Treatment With Glofitamab in R/R B-NHL: a GIMEMA-FIL Study
Gruppo Italiano Malattie EMatologiche dell'Adulto
Unknown
NCT05495828 2023-10-26
Orelabrutinib Therapy in Patients With r/r B-cell Lymphoma Intolerant to Other Bruton Tyrosine Kinase Inhibitors
Peking University People's Hospital
Unknown
NCT04693676 2023-09-28
A Study of C-CAR039 Treatment in Subjects With r/r NHL Subjects Non-Hodgkin's Lymphoma
First Affiliated Hospital of Zhejiang University
Phase 1 Unknown
NCT06045585 2023-09-21
JY231 Injection in the Treatment of Relapsed or Refractory B-cell Lymphoma
Guangdong Second Provincial General Hospital
Phase EARLY_PHASE1 Unknown
NCT05673447 2023-08-28
The Study of Anti-CD19 CAR NK Cells in the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma
Changhai Hospital
Phase EARLY_PHASE1 Unknown
NCT05376709 2023-07-27
A Mixed Methods Study of Nutrition Practice in Cancer Care on Non-Hodgkin Lymphoma Population
National Taiwan University Hospital
Phase NA Unknown
NCT05932173 2023-07-11
A Study of Novel Anti-CD19 CAR-T in Patients With r/r B-Cell Malignancies
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Phase 1/2 Unknown
NCT05771883 2023-05-24
A Clinical Study of Injectable IMM0306 in Combination With Lenalidomide
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Phase 1/2 Unknown
NCT05105867 2023-05-10
CD19 Targeted Universal Chimeric Antigen Receptor T Cells Injection for CD19+ Refractory/Relapsed B-cell Malignancies
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Phase EARLY_PHASE1 Unknown
NCT05797948 2023-04-04
GZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
The First Affiliated Hospital of Soochow University
Phase NA Unknown
NCT05776407 2023-03-20
Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With Refractory or Relapsed B Cell Lymphoma
Chongqing University Cancer Hospital
Phase 1/2 Unknown
NCT05755828 2023-03-06
Clinical Study of Autologous Stem Cell Transplantation + Anti-CD19 CAR T Cells for B-cell Lymphoma
The Affiliated Hospital of Xuzhou Medical University
Phase 2 Unknown
NCT05744037 2023-02-24
Clinical Study of the Safety and Efficacy of the R/R B-NHL Regimen With BTK Inhibitor+Anti-CD19 CAR-T Cells
The Affiliated Hospital of Xuzhou Medical University
Phase 2 Unknown
NCT05739227 2023-02-22
Safety and Efficacy of Allogenic CD19-CAR-NK Cells in Treatmenting r/r B-cell Hematologic Malignancies
Xuzhou Medical University
Phase EARLY_PHASE1 Unknown
NCT05731375 2023-02-16
MUSCLE
UMC Utrecht
Unknown
NCT05322330 2023-02-09
Clinical Study of XPO-1 Inhibitors Plus CAR-T Cells in Relapsed Refractory B-cell Non-Hodgkin's Lymphoma
The First Affiliated Hospital of Soochow University
Phase 2 Unknown
NCT04887025 2023-02-06
Exploratory Study of a Novel Oncolytic Vaccinia Virus RGV004 in the Treatment of Refractory/Relapsed B-cell Lymphoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 1 Unknown
NCT05585996 2023-02-06
Exploratory Clinical Study of CD19-targeted CAR-T and CAR-DC in the Treatment of Relapsed and Refractory B-cell Lymphoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 1 Unknown
NCT05667155 2023-02-06
Clinical Study of Cord Blood-derived CAR NK Cells Targeting CD19/CD70 in Refractory/Relapsed B-cell Non-Hodgkin Lymphoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 1 Unknown
NCT05691153 2023-01-19
ThisCART19A for B-NHL Relapsed After Auto-CAR T
The First Affiliated Hospital of Soochow University
Phase 1 Unknown
NCT04684472 2022-09-26
Modified CD19 CAR-T in Patients With Relapsed or Refractory CD19+ B-cell Malignancies
Sichuan University
Phase 1 Unknown
NCT05453669 2022-07-12
Clinical Study of the Efficacy of CD19-CAR-DNT Cells in the Treatment of Relapsed/Refractory B-cell NHL
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 1 Unknown
NCT05379647 2022-05-18
Natural Killer (NK) Cell Therapy for B-Cell Malignancies
Zhejiang University
Phase 1 Unknown
NCT04246359 2022-04-07
RIPPLE
Sun Yat-sen University
Phase 2 Unknown
NCT05312476 2022-04-05
Clinical Study on CAR-T Targeting Igβ Targets in Refractory Relapsed Non-Hodgkin's Lymphoma
The First Affiliated Hospital of Soochow University
Phase 2 Unknown
NCT03646422 2022-03-31
AEDV Registry of Primary Cutaneous Lymphoma
Fundación Academia Española de Dermatología
Unknown
NCT02481310 2022-02-21
Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma
Northwestern University
Phase 1/2 Unknown
NCT05014100 2021-08-27
Orelabrutinib in Combination With R2 Regimen for R/R CD20+ B-cell Lymphoma
Puyang Oilfield General Hospital
Phase 2 Unknown
NCT04887012 2021-05-14
Clinical Study of HLA Haploidentical CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 1 Unknown
NCT04289220 2021-05-13
Anti-CD19 CAR in PiggyBac Transposon-Engineered T Cells for Relapsed/Refractory B-cell Lymphoma or B-cell Acute Lymphoblastic Leukemia
Yan'an Affiliated Hospital of Kunming Medical University
Phase 1 Unknown
NCT04814004 2021-03-29
Clinical Study of CAR-iNKT Cells in the Treatment of Relapsed/Refractory/High-risk B-cell Tumors
Xuzhou Medical University
Phase 1 Unknown
NCT03000192 2021-03-17
HORIZONS: Understanding the Impact of Cancer Diagnosis and Treatment on Everyday Life
University Hospital Southampton NHS Foundation Trust
Unknown
NCT03245905 2021-03-16
Study of Chidamide as a Single-agent Treatment for Patients With Relapse or Refractory B-NHL
Sun Yat-sen University
Phase 2 Unknown
NCT04796688 2021-03-15
Universal Chimeric Antigen Receptor-modified AT19 Cells for CD19+ Relapsed/Refractory Hematological Malignancies
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 1 Unknown
NCT04747093 2021-02-10
Induced-T Cell Like NK Cells for B Cell Malignancies
Nanfang Hospital, Southern Medical University
Phase 1/2 Unknown
NCT04723914 2021-01-26
CAR-T
Shenzhen University General Hospital
Phase 1/2 Unknown
NCT03559439 2020-11-05
CD19-targeting CAR T Cells in Relapsed or Refractory CD19 Positive B-cell Malignancies
Shanghai Tong Ren Hospital
Phase 1 Unknown
NCT03302403 2020-10-08
Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors
First Affiliated Hospital of Wenzhou Medical University
Phase NA Unknown
NCT04539119 2020-09-04
Entecavir and Tenofovir Versus Entecavir in Lymphoma Patients With Positive HBV DNA
Ruijin Hospital
Phase 3 Unknown
NCT04429438 2020-06-12
Multi-CAR-T Cells Targeting B Cell Lymphomas
Shenzhen Geno-Immune Medical Institute
Phase 1/2 Unknown
NCT04412174 2020-06-02
A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- NHL
Hebei Yanda Ludaopei Hospital
Phase EARLY_PHASE1 Unknown
NCT04264039 2020-02-11
Anti-CD19 U-CAR-T Cell Therapy for B Cell Hematologic Malignancies
Xinqiao Hospital of Chongqing
Phase EARLY_PHASE1 Unknown
NCT04173455 2019-11-22
Study of the Safety, Tolerability and Pharmacokinetics of HZ-A-018 in Patients With B Cell Lymphoma
First Affiliated Hospital of Zhejiang University
Phase 1 Unknown
NCT04169932 2019-11-20
The Clinical Study of CD20 CAR-T Cells in Patients With Relapsed and Refractory B Cell Non-Hodgkin Lymphoma
Shanghai Longyao Biotechnology Inc., Ltd.
Phase EARLY_PHASE1 Unknown
NCT04163302 2019-11-15
Safety and Efficiency Study of CD19-PD1-CART Cell in Relapsed/Refractory B Cell Lymphoma
Chinese PLA General Hospital
Phase 2 Unknown
NCT04028440 2019-09-26
γδT Cells Immunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)
Institute of Hematology & Blood Diseases Hospital, China
Phase EARLY_PHASE1 Unknown
NCT03598179 2019-08-07
XLCART001 Treatment in Relapsed/Refractory/High-risk B-cell Malignancy Subjects
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Unknown
NCT04007978 2019-08-07
Anti-CD22 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy for Relapsed Refractory B-cell Malignancies
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 1 Unknown